Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Names Dr. Daniel S. Grosu Chief Medical Officer

Published: Tuesday, November 01, 2011
Last Updated: Monday, October 31, 2011
Bookmark and Share
As new medical point person for regulators, Grosu to provide medical perspective to project teams, work closely with Illumina clinical services lab.

Illumina, Inc. has announced that it has appointed Dr. Daniel S. Grosu, M.D., as Vice President and Chief Medical Officer. In this newly created position, Dr. Grosu will play a key role in building Illumina's diagnostic capabilities through collaborations with regulatory agencies, internal product development teams, and Illumina's CLIA-certified clinical laboratory.

"Dr. Grosu brings the experience, credentials, and intellectual rigor required to move Illumina's cutting-edge technology into the clinic," said Illumina's Gregory Heath, Senior Vice President and General Manager, Diagnostics.

Heath continued, "As Chief Medical Officer, he will assist in aggressively driving our business towards this enormous new market opportunity."

"During the next few years, we will see tremendous advances in medicine driven by technological breakthroughs in genomics and related systems biology areas," said Dr. Grosu.

Dr. Grosu continued, "These developments will bring us fully into the long-awaited era of personalized medicine, and Illumina is ideally positioned to be both a key enabler and a key player in this historic process. I am delighted to join Illumina at such an exciting time for our industry."

Prior to joining Illumina, Dr. Grosu was Group Director, Clinical Science, Clinical and Medical Affairs at Ortho-Clinical Diagnostics. He was also previously the Director and Global Clinical Leader, Global Clinical Development, Diagnostic Imaging at Bayer Healthcare Pharmaceuticals.

Prior to that, Dr. Grosu was at Siemens Medical Solutions. He holds bachelor's and master's degrees from Wheaton College in Wheaton, Ill., a medical degree from Missouri's Saint Louis University, and a master's degree in business administration from the University of Oxford.

About Dr. Grosu's Compensation

Illumina will grant an option to purchase 60,000 shares of Illumina's common stock and 6,700 restricted stock units (RSUs) to Dr. Grosu as part of his inducement to join the company.

An RSU represents a conditional right to receive one share of our common stock at a specified future date. The options and RSUs were approved by Illumina's compensation committee pursuant to NASDAQ Marketplace Rule 5635(c)(4) and will be granted under Illumina's New Hire Stock and Incentive Plan, which was approved by Illumina's Board of Directors on January 29, 2008.

The option will have the following terms: an exercise price equal to the closing fair market value of Illumina's common stock on the grant date, a ten-year term, and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter.

The RSUs will vest over four years with 25 percent of the RSUs vesting on each of the first four anniversaries of the grant date.

The grant date for the option and RSUs to Dr. Grosu will be his start date with Illumina, which is expected to be October 31, 2011.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina and 10x Genomics Announce Co-Marketing Relationship
Illumina and 10x Genomics have announced building partnership to promote 10x Genomics linked-read sequencing products and Illumina sequencing systems.
Thursday, February 11, 2016
Illumina Files Patent Infringement Suit in the UK Against Premaitha Health
Suit is filed for Infringement of NIPT Patents.
Monday, March 16, 2015
Illumina Revenues Jump 35 Percent
Company’s Third Quarter 2014 Results Announced.
Tuesday, October 21, 2014
Initial Companies Focused on Breakthrough Applications in Therapeutics, Agriculture, and Molecular Pathology
The selection of three startup companies for the inaugural Illumina Accelerator funding cycle are announced.
Wednesday, October 15, 2014
Illumina's HiSeq X Ten Sequencing Technology for Population Studies
Next-generation sequencing technologies to be implemented at new High-Throughput Genomics Center for the MENA region.
Tuesday, July 22, 2014
Illumina Announces Pricing of Convertible Senior Notes
The Notes are being offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Monday, June 09, 2014
Novogene Acquires an Illumina HiSeq X Ten Sequencing System
First-in-China deal Iincreases Novogene's investment in Illumina's Next-Generation Sequencing technology.
Thursday, February 13, 2014
Illumina Announces Recipients of Agricultural Greater Good Initiative Grants
Expanded program focuses on improving food security and furthering agricultural sustainability.
Wednesday, January 16, 2013
Illumina Awarded FDA Contract for NGS Technology to Identify Foodborne Pathogens
Agency selects MiSeq® system for program to explore NGS as mechanism to enhance food safety.
Wednesday, September 19, 2012
The Broad Institute Joins the Illumina Genome Network
Partnership expands the network’s capabilities to enable sequencing of previously inaccessible samples.
Tuesday, June 05, 2012
Cold Spring Harbor Laboratory Joins the Illumina Genome Network
Partnership expands access to large-scale whole genome sequencing.
Monday, May 28, 2012
Macrogen, Inc. Increases Investment in Illumina’s Next-Generation Sequencing Technology
New purchase includes ten HiSeq 2000®Systems, HiSeq 2500® upgrades, and two MiSeq®Systems.
Thursday, March 22, 2012
Illumina Comments on Roche’s Unsolicited Tender Offer Extension
Roche to acquire all outstanding shares of Illumina for $44.50 in cash per common share.
Monday, February 27, 2012
Illumina's Board Unanimously Rejects Roche's Unsolicited Tender Offer
Urges stockholders not to tender their shares, company considers offer inadequate.
Wednesday, February 08, 2012
BCCA Joins the Illumina Genome Network
Network expansion making affordable, high quality whole human genome sequencing services accessible world-wide.
Friday, January 20, 2012
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!